The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gusev E.I.

Pirogov National Research Medical University

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Martynov M.Yu.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnology of the Federal Medical Biological Agency

Blokhin V.E.

Koltsov Institute of Developmental Biology RAS

Kalinkin A.L.

Medical Research and Education Center of Lomonosov Moscow State University

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nodel M.R.

Sechenov First Moscow State Medical University

Malykhina E.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Katunin D.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Gutner U.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Maloshitskaya O.A.

Lomonosov Moscow State University

Sokolov S.A.

Lomonosov Moscow State University

Kucheryanu V.G.

Institute of General Pathology and Pathophysiology

Pavlova E.N.

Koltsov Institute of Developmental Biology RAS

Ugrumov M.V.

Koltsov Institute of Developmental Biology RAS

Development of early diagnosis of Parkinson’s disease based on the search for biomarkers such as premotor symptoms and changes in blood

Authors:

Gusev E.I., Katunina E.A., Martynov M.Yu., Blokhin V.E., Kalinkin A.L., Alessenko A.V., Nodel M.R., Malykhina E.A., Titova N.V., Katunin D.A., Shupik M.A., Gutner U.A., Maloshitskaya O.A., Sokolov S.A., Kucheryanu V.G., Pavlova E.N., Ugrumov M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12): 7‑17

DOI: 10.17116/jnevro20201201217

Read: 6390 times

Contact the author
Table of contents

DEVELOPMENT OF EARLY DIAGNOSIS OF PARKINSON’S DISEASE BASED ON THE SEARCH FOR BIOMARKERS SUCH AS PREMOTOR SYMPTOMS AND CHANGES IN BLOOD
DEVELOPMENT OF EARLY DIAGNOSIS OF PARKINSON’S DISEASE BASED ON THE SEARCH FOR BIOMARKERS SUCH AS PREMOTOR SYMPTOMS AND CHANGES IN BLOOD

To cite this article:

Gusev EI, Katunina EA, Martynov MYu, et al. Development of early diagnosis of Parkinson’s disease based on the search for biomarkers such as premotor symptoms and changes in blood. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(12):7‑17. (In Russ.)
https://doi.org/10.17116/jnevro20201201217

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Change of speech diso­rders during bila­teral deep stimulation of the subthalamic nucleus of the brain in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):59-65
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Current aspe­cts of the rela­tionship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74
Musculoskeletal diso­rders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):6-10
Sele­ction of patients with Parkinson’s disease for inte­rventional therapies: A review of available tools — scales and questionnaires. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):11-17
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Abstract:

OBJECTIVE

To determine changes in the chemical composition of blood plasma in subjects at risk of Parkinson’s disease (PD) at the prodromal stage compared with age control.

MATERIAL AND METHODS

Subjects at risk were selected for the presence of characteristic premotor symptoms, including impairments of sleep, olfaction and constipation.The risk group included 12 people, the control group — 8 people.

RESULTS

Among seven catecholamines and their metabolites detected in the blood, only the concentration of L-dioxiphenylalanine (L-DOPA) changed (decreased) in subjects at risk compared with the control. A decrease in the concentration of L-DOPA is considered as a manifestation (marker) of selective degeneration of central and peripheral catecholaminergic neurons in PD. In contrast to L-DOPA, the concentration of seven of the twelve detected sphingomyelins in the blood of the subjects at risk increased. Given that a change in the metabolism of sphingomyelins is associated with processes such as apoptosis, autophagy, and synucleinopathy, an increase in their concentration in the blood of patients at risk is considered as a manifestation of systemic general degeneration of central and peripheral neurons. Finally, in the blood of subjects at risk, we found a trend towards a decrease in the concentration of urates, which are endogenous neuroprotectors.

CONCLUSION

The changes in the level of L-DOPA, sphingmyelins and urates in the blood of subjects at risk may serve as diagnostic markers of PD at the prodromal stage.

Keywords:

neurodegenerative diseases
Parkinson’ disease
early diagnostics
blood markers
premotor symptoms

Authors:

Gusev E.I.

Pirogov National Research Medical University

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Martynov M.Yu.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnology of the Federal Medical Biological Agency

Blokhin V.E.

Koltsov Institute of Developmental Biology RAS

Kalinkin A.L.

Medical Research and Education Center of Lomonosov Moscow State University

Alessenko A.V.

Institute of Biochemical Physic of the Russian Academy of Sciences

Nodel M.R.

Sechenov First Moscow State Medical University

Malykhina E.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

Katunin D.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Shupik M.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Gutner U.A.

Institute of Biochemical Physic of the Russian Academy of Sciences

Maloshitskaya O.A.

Lomonosov Moscow State University

Sokolov S.A.

Lomonosov Moscow State University

Kucheryanu V.G.

Institute of General Pathology and Pathophysiology

Pavlova E.N.

Koltsov Institute of Developmental Biology RAS

Ugrumov M.V.

Koltsov Institute of Developmental Biology RAS

Received:

03.08.2020

Accepted:

11.08.2020

Close metadata

References:

  1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-1601. https://doi.org/10.1002/mds.26424
  2. Nodel MR. The impact of neuropsychiatric symptoms on quality of life of patients with Parkinson’s disease. Nevrologicheskiy zhurnal. 2015;20(1):20-25. (In Russ.). https://doi.org/10.18821/1560-9545-2015-20-1-20-27
  3. Nodel MR, Ukraintseva UV, Yakhno NN. Rapid eye movements sleep behavioral disorder in Parkinson’s disease. Nevrologicheskiy zhurnal. 2015;20(6):28-34. (In Russ). https://doi.org/10.17116/jnevro20171179115-20
  4. Katunina EA, Ilina EP, Sadekhova GI, Gaisenuk EI. Approaches to early diagnosis of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(6):119-127. (In Russ). https://doi.org/10.17116/jnevro2019119061119
  5. Bezard E, Gross CE. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog Neurobiol. 1998;55(2):93-116.  https://doi.org/10.1016/s0301-0082(98)00006-9
  6. Blesa J, Trigo-Damas I, Dileone M, et al. Compensatory mechanisms in Parkinson’s disease: Circuits adaptations and role in disease modification. Exp Neurol. 2017;298(Pt B):148-161.  https://doi.org/10.1016/j.expneurol.2017.10.002
  7. Agid Y. Parkinson’s disease: pathophysiology. Lancet. 1991;337(8753):1321-1324. https://doi.org/10.1016/0140-6736(91)92989-f
  8. Ugrumov M. Development of early diagnosis of Parkinson’s disease: illusion or reality? CNS Neurosci Ther. 2020;26(10):997-1009. https://doi.org/10.1111/cns.13429
  9. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683. https://doi.org/10.1001/jama.2014.3654
  10. Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol. 2014;4(2):805-826.  https://doi.org/10.1002/cphy.c130026
  11. Braak H, Del Tredici K, Rüb U, et al.. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.  https://doi.org/10.1016/s0197-4580(02)00065-9
  12. Mahlknecht P, Seppi K, Poewe W. The Concept of prodromal Parkinson’s disease. J Parkinsons Dis. 2015;5(4):681-697.  https://doi.org/10.3233/JPD-150685
  13. Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol. 2016;12(11):622-634.  https://doi.org/10.1038/nrneurol.2016.152
  14. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord. 2015;30(2):229-237.  https://doi.org/10.1002/mds.26077
  15. Izawa MO, Miwa H, Kajimoto Y, Kondo T. Combination of transcranial sonography, olfactory testing, and MIBG myocardial scintigraphy as a diagnostic indicator for Parkinson’s disease. Eur J Neurol. 2012;19(3):411-416.  https://doi.org/10.1111/j.1468-1331.2011.03533.x
  16. Shin HY, Joo EY, Kim ST, et al. Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson’s disease and normal control. Neurol Sci. 2013;34(6):935-940.  https://doi.org/10.1007/s10072-012-1164-0
  17. Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative parkinsonism. Nat Rev Neurol. 2009;5(10):561-570.  https://doi.org/10.1038/nrneurol.2009.135
  18. Le W, Dong J, Li S, Korczyn AD. Can Biomarkers help the early diagnosis of Parkinson’s Disease? Neurosci Bull. 2017;33(5):535-542.  https://doi.org/10.1007/s12264-017-0174-6
  19. Kim A, Nigmatullina R, Zalyalova Z, et al. Upgraded methodology for the development of early diagnosis of Parkinson’s Disease based on searching blood markers in patients and experimental models. Mol Neurobiol. 2019;56(5):3437-3450. https://doi.org/10.1007/s12035-018-1315-2
  20. Stiasny-Kolster K, Mayer G, Schäfer S, et al. The REM sleep behavior disorder screening questionnaire — a new diagnostic instrument. Mov Disord. 2007;22(16):2386-2393. https://doi.org/10.1002/mds.21740
  21. Fahn S, Elton RL. UPDRS Development Committee. The Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson’s Disease. 2nd ed. Macmillan Healthcare Information; Florham Park, NJ: 1987;153-163, 293-304. 
  22. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306-1312. https://doi.org/10.1002/mds.20153
  23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.  https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
  24. Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134-139.  https://doi.org/10.1176/jnp.4.2.134
  25. Brown RG, Dittner A, Findley L, Wessely SC. The Parkinson fatigue scale. Parkinsonism Relat Disord. 2005;11(1):49-55.  https://doi.org/10.1016/j.parkreldis.2004.07.007
  26. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment [published correction appears in J Am Geriatr Soc. 2019;67(9):1991]. J Am Geriatr Soc. 2005;53(4):695-699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x
  27. Choi-Kwon S, Han SW, Kwon SU, Kim JS. Poststroke fatigue: characteristics and related factors. Cerebrovasc Dis. 2005;19(2):84-90.  https://doi.org/10.1159/000082784
  28. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600-1611. https://doi.org/10.1002/mds.26431
  29. Kozina EA, Kim AR, Kurina AY, Ugrumov MV. Cooperative synthesis of dopamine by non-dopaminergic neurons as a compensatory mechanism in the striatum of mice with MPTP-induced Parkinsonism. Neurobiol Dis. 2017;98:108-121.  https://doi.org/10.1016/j.nbd.2016.12.005
  30. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.  https://doi.org/10.1139/o59-099
  31. Antoniades CA, Barker RA. The search for biomarkers in Parkinson’s disease: a critical review. Expert Rev Neurother. 2008;8(12):1841-1852. https://doi.org/10.1586/14737175.8.12.1841
  32. Yu Z, Stewart T, Aasly J, et al. Combining clinical and biofluid markers for early Parkinson’s disease detection. Ann Clin Transl Neurol. 2017;5(1):109-114.  https://doi.org/10.1002/acn3.509
  33. Li T, Le W. Biomarkers for Parkinson’s Disease: How Good Are They? Neurosci Bull. 2020;36(2):183-194.  https://doi.org/10.1007/s12264-019-00433-1
  34. Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901-905.  https://doi.org/10.1007/s00702-017-1686-y
  35. Marino BLB, de Souza LR, Sousa KPA, et al. Parkinson’s Disease: A Review from pathophysiology to treatment. Mini Rev Med Chem. 2020;20(9):754-767.  https://doi.org/10.2174/1389557519666191104110908
  36. Alessenko AV, Albi E. Exploring sphingolipid implications in neurodegeneration. Front Neurol. 2020;11:437.  https://doi.org/10.3389/fneur.2020.00437
  37. Nixon GF. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br J Pharmacol. 2009;158(4):982-993.  https://doi.org/10.1111/j.1476-5381.2009.00281.x
  38. Norris GH, Blesso CN. Dietary and endogenous sphingolipid metabolism in chronic inflammation. Nutrients. 2017;9(11):1180. https://doi.org/10.3390/nu9111180
  39. Jembrek MJ, Hof PR, Šimić G. Ceramides in Alzheimer’s Disease: key mediators of neuronal apoptosis induced by oxidative stress and Aβ accumulation. Oxid Med Cell Longev. 2015;2015:346783. https://doi.org/10.1155/2015/346783
  40. Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016;37(7):8471-8486. https://doi.org/10.1007/s13277-016-5035-9
  41. Mao CY, Yang J, Wang H, et al. SMPD1 variants in Chinese Han patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord. 2017;34:59-61.  https://doi.org/10.1016/j.parkreldis.2016.10.014
  42. Foo JN, Liany H, Bei JX, et al. Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson’s disease. Neurobiol Aging. 2013;34(12):37-42.  https://doi.org/10.1016/j.neurobiolaging.2013.06.010
  43. Kim WS, Halliday GM. Changes in sphingomyelin level affect alpha-synuclein and ABCA5 expression. J Parkinsons Dis. 2012;2(1):41-46.  https://doi.org/10.3233/JPD-2012-11059
  44. den Jager WA. Sphingomyelin in Lewy inclusion bodies in Parkinson’s disease. Arch Neurol. 1969;21(6):615-619.  https://doi.org/10.1001/archneur.1969.00480180071006
  45. Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(5):365-375.  https://doi.org/10.1038/nrn1100
  46. Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res. 2007;11(3-4):151-167.  https://doi.org/10.1007/BF03033565
  47. Cicchetti F, Drouin-Ouellet J, Gross RE. Environmental toxins and Parkinson’s disease: what have we learned from pesticide-induced animal models? Trends Pharmacol Sci. 2009;30(9):475-483.  https://doi.org/10.1016/j.tips.2009.06.005
  48. Guedes LC, Chan RB, Gomes MA, et al. Serum lipid alterations in GBA-associated Parkinson’s disease. Parkinsonism Relat Disord. 2017;44:58-65.  https://doi.org/10.1016/j.parkreldis.2017.08.026
  49. Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson’s disease risk, diagnosis and prognosis. Biomark Med. 2010;4(5):701-712.  https://doi.org/10.2217/bmm.10.94
  50. Wen M, Zhou B, Chen YH, et al. Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis. PLoS One. 2017;12(3):e0173731. https://doi.org/10.1371/journal.pone.0173731
  51. Uribe-San Martín R, Venegas Francke P, López Illanes F, et al. Plasma urate in REM sleep behavior disorder. Mov Disord. 2013;28(8):1150-1151. https://doi.org/10.1002/mds.25441
  52. van Wamelen DJ, Taddei RN, Calvano A, et al. Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson’s Disease. J Parkinsons Dis. 2020;10(3):1003-1010. https://doi.org/10.3233/jpd-201988
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.